Ionis Pharmaceuticals And Partner Roche Said Prespecified Interim Results From Phase 3 IMAgINATION Study Of Sefaxersen For Primary IgA Nephropathy Met Its Primary Endpoint Of Statistically Significant And Clinically Meaningful Improvements In Proteinuria Reduction Vs. Placebo At 37 Weeks
– Sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential –– IgAN is a progressive kidney disease that is
Ionis and Roche's new kidney medicine passed a big test. It reduced protein in urine better than a fake pill, which hints the drug could help patients.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.